688315.SHG Novogene Co. Ltd.
- Market cap
- CNY 7.18B
- P/E
- 44.2x
- P/B
- 2.53x
- ROE
- 4.7%
- Dividend yield
- 0.28%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688315.SHG undervalued?
Graham number688315.SHG trades 122.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Novogene Co. Ltd. fundamental analysis
No fundamental analysis for Novogene Co. Ltd. yet.
Novogene Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Novogene Co. Ltd.
Novogene Co., Ltd., together with its subsidiaries, provides genomic services and solutions in Mainland China, Hong Kong, Macau, Taiwan, and internationally. The company offers genomic solutions comprising human, animal, plant, and microbial whole genome sequencing, as well as human and mouse whole exome sequencing, microbial de novo sequencing, animal and plant de novo sequencing, and 16S/18S/ITS amplicon and shotgun metagenomic sequencing; transcriptomics solutions, such a…
Full company profileNovogene Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Novogene Co. Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 458M | 739M | 1.05B | 1.53B | 1.49B | 1.87B | 1.93B | 2.00B | 2.11B | 2.21B | 2.23B |
| Gross Profit | 220M | 316M | 452M | 601M | 518M | 794M | 849M | 852M | 918M | 940M | 952M |
| Operating Income | 44.3M | 88.9M | 113M | 119M | 36.1M | 246M | 212M | 215M | 234M | 194M | 129M |
| EBITDA | 71.8M | 139M | 195M | 211M | 152M | 366M | 323M | 344M | 360M | 194M | 151M |
| Net Income | 39.1M | 80.5M | 97.1M | 114M | 36.5M | 225M | 177M | 178M | 197M | 166M | 128M |
| EPS | 0.34 | 0.22 | 0.27 | 0.32 | 0.10 | 0.58 | 0.44 | 0.44 | 0.48 | 0.41 | 0.31 |
| Balance Sheet | |||||||||||
| Total Assets | 1.23B | 1.35B | 1.47B | 1.97B | 2.02B | 2.86B | 3.05B | 3.59B | 3.64B | 3.94B | 3.93B |
| Total Liabilities | 434M | 488M | 499M | 883M | 904M | 1.06B | 1.07B | 1.12B | 1.12B | 1.26B | 1.19B |
| Shareholders' Equity | 793M | 863M | 968M | 1.08B | 1.12B | 1.79B | 1.96B | 2.46B | 2.49B | 2.65B | 2.71B |
| Cash & Short-term Investments | 253M | 158M | 189M | 368M | 490M | 1.06B | 1.04B | 1.53B | 1.64B | 482M | 472M |
| Total Debt | 94.9M | 52.1M | - | 182M | 71.3M | 44.8M | 49.3M | 17.8M | 13.8M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 95.4M | 54.8M | 151M | 85.4M | 342M | 293M | 304M | 334M | 386M | 217M | - |
| Capital Expenditure | 128M | 497M | 81.1M | 173M | 92.1M | 112M | 217M | 117M | 183M | 104M | 144M |
| Free Cash Flow | -32.4M | -442M | 70.3M | -87.2M | 250M | 181M | 86.7M | 217M | 203M | 113M | -83.2M |
| Ratios | |||||||||||
| ROE | 4.9% | 9.3% | 10.0% | 10.6% | 3.3% | 12.6% | 9.0% | 7.2% | 7.9% | 6.3% | 4.7% |
| ROA | 3.2% | 6.0% | 6.6% | 5.8% | 1.8% | 7.9% | 5.8% | 5.0% | 5.4% | 4.2% | 3.3% |
| Net Profit Margin | 8.5% | 10.9% | 9.2% | 7.4% | 2.5% | 12.1% | 9.2% | 8.9% | 9.3% | 7.5% | 5.8% |
| Debt to Equity | 0.12x | 0.06x | - | 0.17x | 0.06x | 0.03x | 0.03x | 0.01x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Novogene Co. Ltd. dividends
- Dividend yield
- 0.28%
- Forward dividend
- 0.05 CNY
- Payout ratio
- 12.2%
- Ex-dividend date
- Jun 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 20.3M | 0.05 | 12.2% |
| 2024 | CNY 19.4M | 0.05 | 9.9% |
| 2023 | CNY 19.5M | 0.05 | 10.9% |
| 2022 | CNY 24.3M | 0.06 | 13.7% |
| 2021 | CNY 2.48M | 0.01 | 1.1% |
| 2020 | CNY 9.27M | 0.03 | 25.4% |
| 2019 | CNY 2.33M | 0.01 | 2.0% |
| 2018 | 557K | 0.00 | 0.6% |
| 2017 | 1.85M | 0.01 | 2.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Novogene Co. Ltd.
- Insiders 66.67%
- Institutions 6.19%
- Public & others 27.15%
- Shares outstanding 416M
- Free float 139M
Novogene Co. Ltd. company profile
- Company name
- Novogene Co. Ltd.
- Ticker
- 688315.SHG
- ISIN
- CNE1000052X3
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,225
- Fiscal year end
- December
- Address
- Building 301, Beijing, China, 100015
- Phone
- 86 10 8283 7801
- Website
- novogene.com
About Novogene Co. Ltd.
Novogene Co., Ltd., together with its subsidiaries, provides genomic services and solutions in Mainland China, Hong Kong, Macau, Taiwan, and internationally. The company offers genomic solutions comprising human, animal, plant, and microbial whole genome sequencing, as well as human and mouse whole exome sequencing, microbial de novo sequencing, animal and plant de novo sequencing, and 16S/18S/ITS amplicon and shotgun metagenomic sequencing; transcriptomics solutions, such as mRNA, long non-coding RNA, small RNA, circular RNA, whole transcriptome, isoform, direct RNA, prokaryotic RNA, and meta transcriptome sequencing; and single cell gene expression, single cell long road read transcriptome, and visium formalin-fixed paraffin-embedded spatial transcriptome solutions. It also provides epigenomic solutions comprising whole genome bisulfite, reduced representation bisulfite, chromatin immunoprecipitation, and RNA immunoprecipitation sequencing; premade library and proteomics services; clinical diagnostics services, such as clinical whole exome sequencing and clinical panels; biopharma services consisting of discovery and pre-clinical, translational and clinical, and companion diagnostics; and support services. In addition, the company offers sequencing platforms under the ILLUMINA, PACBIO, 10X GENOMICS, and NANOPORE brands; and basic scientific research services in life sciences, and medical research and technical services. Its services are used in cancer research, immuno-oncology agrigenomics, environment, food science, human microbiome, plant and animal microbiome, drug discovery and development, and rare and complex diseases applications. The company serves research universities, research institutes, hospitals, pharmaceutical research and development companies, and agricultural companies. Novogene Co., Ltd. was founded in 2011 and is headquartered in Beijing, China.
Novogene Co. Ltd. management
4- Dr. Ruiqiang LiFounder, Chairman of the Board & CEO · born 1980
- Mr. Jiashan ShiFinancial Director · born 1983
- Mr. Qifeng WangDeputy GM, Secretary of the Board of Directors & Director · born 1979
- Weisheng ChenAccounting Supervisor